Finch Therapeutics Group, Inc. financial data

Symbol
FNCH on OTC
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2024 - 13 Aug 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 557% % 16%
Debt-to-equity 157% % 100%
Return On Equity -69% % 65%
Return On Assets -27% % 76%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,605,763 shares 0.06%
Common Stock, Shares, Outstanding 1,605,763 shares 0.06%
Common Stock, Value, Issued $2,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 1,605,763 shares 0.06%
Weighted Average Number of Shares Outstanding, Diluted 1,605,763 shares 0.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD -100%
Research and Development Expense $0 USD -100%
General and Administrative Expense $19,689,000 USD -47%
Operating Income (Loss) $19,504,000 USD 86%
Nonoperating Income (Expense) $5,337,000 USD 36%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $14,167,000 USD 90%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $14,167,000 USD 90%
Earnings Per Share, Basic -8 USD/shares 92%
Earnings Per Share, Diluted -8 USD/shares 92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $16,035,000 USD -53%
Assets, Current $17,279,000 USD -53%
Property, Plant and Equipment, Net $507,000 USD -31%
Operating Lease, Right-of-Use Asset $25,441,000 USD -6.8%
Assets $45,576,000 USD -32%
Accounts Payable, Current $29,000 USD -93%
Liabilities, Current $4,462,000 USD -53%
Operating Lease, Liability, Noncurrent $26,895,000 USD -8.5%
Liabilities $31,357,000 USD -20%
Retained Earnings (Accumulated Deficit) $359,105,000 USD -4.1%
Stockholders' Equity Attributable to Parent $14,219,000 USD -49%
Liabilities and Equity $45,576,000 USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,362,000 USD 67%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 1,605,763 shares 0.06%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,362,000 USD 85%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18,384,000 USD
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid $39,605,000 USD
Operating Lease, Liability, Current $2,094,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year Two $5,071,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $4,931,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $5,215,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $5,364,000 USD
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years $4,931,000 USD -21%
Depreciation, Depletion and Amortization $43,000 USD -97%
Operating Leases, Future Minimum Payments Due, Next Twelve Months $3,197,000 USD -30%
Share-based Payment Arrangement, Expense $492,000 USD -91%
Operating Leases, Future Minimum Payments, Due in Three Years $5,071,000 USD -21%
Operating Leases, Future Minimum Payments Due $40,804,000 USD -19%